New S$1.4b Biomedical Sciences Hub to House A*STAR, R&D Firms

Why It Matters

The hub accelerates Singapore’s transition to a high‑value biotech hub, drawing global R&D spend and fostering innovation‑driven employment.

Key Takeaways

• Singapore invests S$1.4 bn in new biomedical sciences hub.
• Hub will host A*STAR and leading global biotech firms.
• Barry Kalibo Group opens AI‑driven chocolate innovation center.
• Facility spans 25 football fields; 80% business occupancy achieved.
• Hub supports Singapore’s S$37 bn RIE plan and talent ecosystem.

Summary

Singapore announced a S$1.4 billion biomedical sciences hub that will house the nation’s public research agency A*STAR alongside leading multinational biotech firms. The development is part of a broader S$37 billion commitment to research, innovation and enterprise over the next five years, aiming to cement the city‑state’s status as a regional R&D powerhouse. The 25‑football‑field complex offers state‑of‑the‑art laboratories, flexible workspaces and custom infrastructure, with business occupancy already at 80 percent. Private residential units nearby sold out instantly, underscoring strong demand. Notably, Barry Kalibo Group, a Singapore‑based chocolate innovator that partners with Nestlé, will launch its first global AI‑driven innovation centre within the hub, pioneering new confectionery products. Minister for Trade and Industry Dr Tan See Leng highlighted the hub as a tangible sign of Singapore’s commitment to high‑value, technology‑led growth, stressing that the nation must compete on innovation rather than scale. He referenced the hub’s proximity to universities, the One‑North ecosystem, JTC Launchpad and the upcoming Kumbong AI facility as critical talent and collaboration enablers. The hub’s launch signals a deepening of Singapore’s life‑sciences cluster, attracting foreign R&D investment, creating high‑skill jobs and reinforcing the country’s value‑chain position in biotech and related sectors.

Original Description

A new S$1.4 billion biomedical sciences hub will house Singapore's public R&D agency A*STAR and some of the world's leading biomedical firms. The space, called Geneo, comes as Singapore has committed S$37 billion into research, innovation and enterprise over the next five years. Rachel Teng reports.